

SUPPLEMENTARY DATA

Supplementary Figure S1

SIP(F8):

Sequence of monomer: EVQLLES GGGGLVQP GGSRLRLSCAASGFT
FSLFTMSWVRQAPGKGLEWVSAISGSGGSTYYADSVK
GRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAKSTHLY
LFDYWGQGT LVTVSSGGGGSGGGGGSGGGGGEIVLTQSP
GTL^{**S**}LSLSPGERATLSCRASQSVSMPFLAWYQQKPGQAPR
LLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAV
YYCQQMRGRPPTFGQGTKVEIKSGGSGGPRAAPEVYAF
ATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLP
DARHSTTQPRKTKGSGFFVFSRLEVTRAWEQKDEFIC
RAVHEAASPSQTVQRAVSVNPESRRGGC

Calculated mass of monomer: 38728

IgG(F8) HC:

EVQLLES GGGGLVQP GGSRLRLSCAASGFTFSLFTMSWVR
QAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDN SK
NTLYLQMNSLRAEDTAVYYCAKSTHLYLFDYWGQGT L
VTVSSASTKGPSVFLAPSSKSTSGGTAALGCLVKDYFP
EPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVP
SSSLGTQTYICNVNHKPSNTKVDKKVEPKS^{**S**}DKTHT^{**S**}P
P^{**S**}PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV
SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVV
SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKG
QPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVE
WESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFS^{**C**}SV MHEALHNHYTQKSLSLSPGK

Calculated Mass of Heavy Chain: 48796


IgG(F8) LC:

EIVLTQSPGTL^{**S**}LSLSPGERATLSCRASQSVSMPFLAWYQQ
KPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISR
LEPEDFAVYYCQQMRGRPPTFGQGTKVEIKRTVAAPSVF
IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAL
QSGNSQESVTEQDSKDSSTLSSTLTLSKADYEKHKVY
ACEVTHQGLSSPVT^{**K**}SFNRGEC

Calculated Mass of Light Chain: 23480


Amino acid sequences and calculated mass of SIP(F8) monomer and IgG(F8) light and heavy chain. Cysteines used for conjugation are highlighted in bold.

Supplementary figure S2




SIP(F8)-SS-DM1 stability : ESI-MS spectra of the SIP(F8)-SS-DM1 conjugate after 0 and 3 h of incubation in mice serum in presence of the SIP(F8)-IAA internal standard (Calculated mass = 38784 Da).

Supplementary figure S3



IgG(F8)-SS-DM1 release test : ESI-MS spectra of the IgG(F8)-SS-DM1 conjugate after 0 and 1 h of incubation in mice serum in presence of 1mM DTT.

Supplementary figure S4



Schematic representation of a proposed mechanism for the formation of disulfide-bonded SIP products, upon cleavage of a first mixed disulfide bond between antibody moiety and DM1-SH drug.

Supplementary table S1: Biodistribution results

	SIP(F8)-SS-DM1			IgG(F8)-SS-DM1		
	3h	24h	48h	3h	24h	48h
Tumor	8.18 ± 1.23	7.80 ± 1.97	3.11 ± 0.52	12.18 ± 0.97	32.80 ± 1.37	24.96 ± 2.61
Liver	1.84 ± 0.89	0.32 ± 0.09	0.12 ± 0.01	9.74 ± 0.57	4.51 ± 0.50	2.85 ± 0.18
Lung	5.33 ± 2.71	0.69 ± 0.35	0.21 ± 0.15	29.23 ± 1.60	11.99 ± 2.15	5.54 ± 2.73
Spleen	1.65 ± 0.83	0.39 ± 0.12	0.11 ± 0.06	5.35 ± 2.82	3.63 ± 0.27	1.13 ± 0.63
Heart	2.11 ± 0.14	0.22 ± 0.04	0.07 ± 0.01	4.72 ± 4.36	3.94 ± 0.58	2.73 ± 0.10
Kidney	9.75 ± 0.12	0.42 ± 0.18	0.28 ± 0.11	13.45 ± 3.69	7.08 ± 0.20	4.05 ± 1.15
Colon	0.38 ± 0.33	0.08 ± 0.03	0.18 ± 0.09	4.47 ± 4.37	7.36 ± 0.98	1.38 ± 0.70
Stomach	1.71 ± 0.38	0.61 ± 0.23	0.20 ± 0.18	1.36 ± 1.11	5.99 ± 0.99	3.13 ± 1.37
Blood	6.62 ± 0.08	0.77 ± 0.08	0.29 ± 0.03	33.49 ± 0.13	15.62 ± 2.04	9.4 ± 0.89

Results of biodistribution experiments, performed in F9 tumor-bearing mice with radioiodinated ADC preparations. Details are presented in the experimental procedures section. Results are expressed as the percent of antibody injected activity per gram of tissue (%IA/g) ± SD